Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation

What is known and objective:  Tacrolimus, a widely used immunosuppressive agent in organ transplantation, has a narrow therapeutic window. It has been suggested that its interaction with lansoprazole could be dependent on polymorphisms of CYP3A5 and CYP2C19. The objective of this study was to investigate how, 1 year after renal transplantation, CYP3A5 and CYP2C19 polymorphisms, biochemical parameters and coadministration with lansoprazole, influenced tacrolimus pharmacokinetics.

[1]  T. Habuchi,et al.  No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients , 2008, Journal of clinical pharmacy and therapeutics.

[2]  T. Habuchi,et al.  Influence of Lansoprazole and Rabeprazole on Mycophenolic Acid Pharmacokinetics One Year After Renal Transplantation , 2008, Therapeutic drug monitoring.

[3]  S. Uemoto,et al.  Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. , 2008, Drug metabolism and pharmacokinetics.

[4]  A. B. Ruzilawati,et al.  Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[5]  Kyungsoo Park,et al.  Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. , 2007, British journal of clinical pharmacology.

[6]  T. Habuchi,et al.  Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients , 2007, Biopharmaceutics & drug disposition.

[7]  B. Vinet,et al.  Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients , 2006, Pharmacogenetics and genomics.

[8]  Robert E. Smith,et al.  Delayed gastric ulcer healing associated with sirolimus. , 2006, Transplantation.

[9]  T. Habuchi,et al.  Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction. , 2006, Journal of pharmaceutical and biomedical analysis.

[10]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[11]  D. Hesselink,et al.  The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? , 2005, Pharmacogenomics.

[12]  T. Habuchi,et al.  Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. , 2005, Transplantation proceedings.

[13]  T. Habuchi,et al.  Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  B. Suwelack,et al.  Resolution of severe MMF-related gastrointestinal adverse events following conversion to enteric-coated mycophenolate sodium. , 2005, Transplantation.

[15]  Jun He,et al.  CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[16]  N. Ohkohchi,et al.  Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations , 2004, The Journal of pharmacy and pharmacology.

[17]  K. Shu,et al.  Risk factors for peptic ulcer disease in renal transplant patients--11 years of experience from a single center. , 2004, Clinical nephrology.

[18]  M. Miura,et al.  Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  O. Ogawa,et al.  Lansoprazole—Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism , 2004, The Annals of pharmacotherapy.

[20]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[21]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[22]  J. Azuma,et al.  Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. , 2002, Pharmacogenetics.

[23]  Ann Daly,et al.  Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. , 2002, Pharmacogenetics.

[24]  M. Homma,et al.  Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. , 2002, Transplantation.

[25]  U. Christians,et al.  Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus , 2002, Clinical pharmacokinetics.

[26]  H. Mohrenweiser,et al.  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. , 2001, The Journal of pharmacology and experimental therapeutics.

[27]  A Johnston,et al.  Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration–Time Curve: Review of Current Algorithms , 2001, Therapeutic drug monitoring.

[28]  M. Lai,et al.  Novel mutations of CYP3A4 in Chinese. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[29]  T. Suzuki,et al.  A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. , 1999, Biological & pharmaceutical bulletin.

[30]  S. Higuchi,et al.  Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. , 1999, British journal of clinical pharmacology.

[31]  C. Nakamura,et al.  Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects , 1997, European Journal of Clinical Pharmacology.

[32]  J. Goldstein,et al.  Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. , 1997, Pharmacogenetics.

[33]  L. Bertilsson,et al.  CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. , 1996, Pharmacogenetics.

[34]  J. Balian,et al.  Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype , 1996, Clinical pharmacology and therapeutics.

[35]  A. D. Rodrigues,et al.  Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.

[36]  C. Bonfils,et al.  Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.

[37]  D. Dunn,et al.  Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. , 1995, Journal of the American College of Surgeons.

[38]  L. Bertilsson,et al.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[39]  I. Yamatsu,et al.  Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. , 1991, Biochemical pharmacology.

[40]  H. Satoh,et al.  Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[41]  N. Takeguchi,et al.  The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor. , 1990, Biochemical pharmacology.

[42]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[43]  G. Wilkinson,et al.  Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.